SUNNYVALE, Calif. - Smartlens, a clinical-stage ophthalmic technology company advancing next-generation glaucoma management devices, has announced the closing of an oversubscribed $5.2 million bridge round. The financing will be used to advance the FDA clearance process and prepare for an expedited market launch following clearance.
miLens is distinguished as the world's first electronics-free contact lens technology capable of continuous intraocular pressure (IOP) monitoring. Working with Smartlens' AI-powered smartphone imaging platform, miLens captures critical pressure fluctuations and enables data-driven treatment optimization. The company plans to initiate commercial activities following FDA clearance, marking a major milestone in transforming glaucoma care worldwide.
Building on strong clinical progress in its multi-site U.S. pivotal trial, Smartlens has made advancements in regulatory preparation, manufacturing scale-up and clinical validation.
miLens is the world's smallest wearable microfluidic device designed as an electronics-free soft contact lens for continuous, real-world monitoring of intraocular pressure outside of clinical settings. An independent, double-blind survey of 166 ophthalmic practitioners conducted by Market Scope showed exceptionally high interest, with 96.2% expressing intent to adopt the technology once available. miLens offers unprecedented insight for patients with glaucoma, ocular hypertension, and those requiring post-surgical intraocular pressure monitoring.
Savas Komban, CEO and Co-Founder of Smartlens, said, "This financing milestone strengthens our position as we advance through the FDA clearance process and prepare for commercialization. We're laying the foundation for the next generation of glaucoma management—one driven by continuous, data-based insight rather than intermittent snapshots. The continued confidence from our investors underscores both the scale of the opportunity ahead and the meaningful impact miLens can have for patients worldwide."
